Another NASH hopeful falls short in Phase III test

12 May 2020
2019_biotech_test_lab_development_big

A trial miss for French metabolic specialist Genfit (Euronext: GNFT) has sent investors running scared in pre-market trading.

Ahead of the opening bell in New York, shares in the company were down over 60%, after the firm revealed the Phase III RESOLVE-IT study of elafibranor missed its primary endpoint.

The response rate was 19.2% for people who received elafibranor, a dual PPARα/δ agonist, compared to 14.7% for people in the placebo arm.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology